Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on CBIO stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Stephen Willey has given his Buy rating due to a combination of factors that highlight Crescent Biopharma’s strategic positioning and growth potential. The recent agreement with Sichuan Kelun-Biotech significantly enhances Crescent’s pipeline, granting them rights to a promising antibody-drug conjugate (ADC) outside of Greater China. This deal not only provides Crescent with a clinically-validated target antigen but also allows them to explore combination therapies, setting them apart from competitors in the PD-1xVEGF-A landscape.
Furthermore, the company has disclosed an ambitious development strategy for their CR-001 monotherapy, targeting a range of solid tumor types. The planned Phase 1/2 trial is designed to quickly identify promising signals across prioritized tumors, with preliminary data expected in early 2027. This strategic approach, coupled with a solid financial runway, positions Crescent Biopharma to establish a competitive edge and achieve clinical differentiation, justifying the Buy rating.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.